Celiac Disease, Gluten-Free Diet, and Bone Mass Density

Vida Mohammad Parast; BSc1, Zamzam Paknahad; PhD2

1 Department of Nutrition, School of Nutrition and Food Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
2 Department of Clinical Nutrition, School of Nutrition and Food Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.

ARTICLE INFO

ABSTRACT

Background: Celiac disease (CD), as an autoimmune disease has initiated since ingestion of food containing gluten. Constant intolerance to gluten causes damages of the small intestinal mucosa. One reason of mal-absorption in children and infants is CD. Additionally, about 75% of newly identified patients with CD have low bone mineral density (BMD). Many factors have role in metabolic bone diseases, such as disturbance in calcium absorption, consumption of endogenous calcium, fecal loss, damaged to vitamin D absorption, and inflammatory mediators. The gluten free diet (GFD) is the only efficacious treatment for CD. Low BMD which is a prevalent problem of untreated CD may be restored by GFD. Methods: Databases of PubMed, Web of science, Google scholar, Scopus and Embase were searched by the following keywords: CD and GFD, CD and BMD, GFD and children up to July 2016. Results: Most children with CD already have reduced bone mass density before treatment with GFD. GFD caused normal bone mineral density in most of celiac children and adolescent. The treatment duration for restoration of bone mass was not obvious. There were no similar time points for all patients, thus the duration of treatment was different. There was a relationship between age of patients at diagnosis and therapeutic intervention and recovery of BMD; older children may have slower grades of improvement. Conclusions: GFD has an important role in bone health. If CD is diagnosed and managed before adolescence, children with CD may achieve normal bone mass.

Keywords: Celiac; Gluten free diet; Bone mineral density

Introduction

Celiac disease (CD) is a chronic autoimmune disorder related to the small intestines, individuals with such disease are genetically susceptible to dietary gluten due to disease stimulation. Main characteristic of CD is subtotal or total atrophy of intestinal villi disease and intestinal mal-absorption, which was improved by gluten-free diet (GFD) (Fasano, 2005). Prolamine polypeptides or gluten is found in wheat, rye, barley, and other closely-related grains (Ribaldone et al., 2011). In genetically susceptible individuals, gluten causes an inflammatory reaction in the jejunum predominantly. Small intestinal mucosa damage induced by gluten will ultimately decrease the
intestinal absorptive region and restrict absorption of micronutrients (Fasano, 2005, Pantaleoni et al., 2014). In the general population, prevalence of CD was stated about 1% at any age (Blume and Curtis, 2011, Rampertab et al., 2006). Classical symptoms, such as diarrhea and mal-absorption are common in childhood but there are a wider spectrum of symptoms in adults than children (Pantaleoni et al., 2014). Strict adherence to GFD makes the nutritional status better (Stazi, 2013).

Clinical manifestations of CD are on a wide spectrum, immune response is mainly targeted at the intestinal mucosa; but it also affects other tissues or organs. One of the main extra-intestinal manifestations of CD is low bone mineral density (BMD) which decreases bone mass while raises bone frailty and risk of breaks (Kotze and SRR, 2011). Inflammation and intestinal mal-absorption influence the pathophysiology of bone in CD (Molteni et al., 1995). Several reports have confirmed that patients with untreated CD have BMD (Barera et al., 2004, Kalayci et al., 2001, Kavak et al., 2003, Mora, 2003, 2008, Mora et al., 2001). Metabolic bone disease has a multifactorial etiology, including damage in absorption and consequently fecal loss of vitamin D and calcium. It also causes disruption of normal bone turnover since inflammatory moderator influences bone cell (Barera et al., 2004, Mora, 2008, Taranta et al., 2004). Osteopenia as a typical public health problem in adults can be identified and stopped in childhood. Maximum of the bone mass is attained throughout the first two decades of life, therefore, early identification of CD and adherence to the gluten-free diet (GFD) has an important role in obtaining sufficient bone metabolism in such patients (Chesnut 3rd, 1989, Lu et al., 1994).

Early treatment in pediatric CD patients has been proved to cause considerably greater bone metabolic rates. So, remedy switches the inflammatory process and stops damage of bone mass gaining during the most important period of its growth (Kavak et al., 2003, Mora, 2003, Mora et al., 1999). The aim of the present review was to investigate the gluten free diet and BMD in children with CD.

Materials and Methods

The following databases of PubMed, Web of science, Google scholar, Scopus and Embase were searched by using these keywords: CD and GFD, CD and BMD, as well as GFD and children up to July 2016.

Results

Pathogenesis: CD is a multi-gene disorder that is related with human leukocyte antigen (HLA) genes. Alleles encoding HLA-DQ2 were inherited in 90% to 95% of celiac patients and remaining of patients have HLA-DQ8 (Johnson et al., 2004, Ploski et al., 1993). In pathogenesis of CD, expression of HLA-DQ2 or HLA-DQ8 is essential but not enough. Furthermore, environmental factors such as infections (Plot and Amital, 2009), some drugs (Cammarota et al., 2000), smoking (Vazquez et al., 2001), breastfeeding, and the beginning time of gluten intake (Akobeng et al., 2006) may influence disease incidence. Most of cases diagnosed with widespread serological testing (James, 2005, Lo et al., 2003, Murray et al., 2003). This disease is common in adults more than pediatric and it is predominately in females. Young adults and patients older than 60 years are the most newly diagnosed CD patients. Only in severe illness, ileum and colon are damaged. CD mostly influences the mucosa of the proximal small intestine so that the severity of injury is slowly reducing towards the distal small intestine (Ciclitira and Moodie, 2003). The clinical appearance of CD is widespread and thus influenced by patients’ age, period and degree of disease, as well as existence of extra-intestinal signs (Chand and Mihas, 2006). These patients may have severely symptomatic or asymptomatic. Mostly CD patients have mal-absorption sings related to concomitant symptoms of autoimmune disorders. Symptoms such as diarrhea, constipation, abdominal emphysema, vomiting, weight loss, infirmity, short stature, flatus, muscle losses and hypotonia, as well as usual irritability and depression were observed in children, adolescents, and adults with CD (Fasano, 2005, Green, 2005). There are usual symptoms including hypocalcemia, vitamin D deficiency, low bone foundation, boosted bone resorption signs, and
low BMD in children and adolescents with untreated CD. Gastrointestinal (GI) symptoms in minor CD patients may not be present or not distinguished, but patients might state irrelevant sings such as indigestion, stomach ache, bloating inexplicable anemia, fatigue, hypertransaminasemia, sterility, neurologic disorders, short stature dermatitis herpetiforms, and osteoporosis (Rampertab et al., 2006).

Intestinal mucosal abnormalities are characteristics of the silent form of CD that are apparently asymptomatic but majority of patients have positive serologic test (Rashtak and Murray, 2012). The relationship among autoimmune and immune-mediated diseases, such as autoimmune thyroiditis, morphea, and type 1 diabetes mellitus, with CD has been investigated (Tack et al., 2010). In addition, Down, Turner, or Williams syndromes increased the risk for incident of CD (Shaoul and Lerner, 2007). Elimination of gluten from the diet is a basis of CD management (Giannotti et al., 2001).

In a GFD, it is generally accepted that barley, wheat, and rye must be evaded because of their prolamins (gliadin, hordein, and secalin) which are the initiating factors of CD (Rashtak and Murray, 2012). Most celiac patients can tolerate 50 mg of gluten per day. Amounts equal to or more than 100 mg per day can cause appearance of symptoms. Gluten free food have less than or equal to 20 mg/kg (20 ppm) of gluten (Bioletti et al., 2016).

**Children and low BMD:** CD children are at risk for decreased BMD. Decreased BMD and bone mineral content (BMC) have been frequently observed in children and adolescents with untreated CD (Barera et al., 2004, Mora et al., 1998). Clinical presentations such as reduced BMD, significantly upper parathormon (PTH), and reduced serum calcium were reported in untreated children with CD in comparison with treated and control groups (Mora et al., 1999). In this regard, reduced BMD was reported in untreated CD children (Barera et al., 2004), also a study on young children (mean age of 4.9 years) with CD indicated reduced BMD and severe osteopenia in 17% of CD children at the time of diagnosis (Tau et al., 2006). In another study, bone status in CD children was evaluated; it was observed that BMD reduced significantly even after 1 or at least 2 years of GFD than the control population.

CD children are at risk for less-than-optimum peak bone mass gaining and a delayed growth. The peak quick acquisition of bone mass happens throughout adolescence. Peak value of bone mass is achieved at the end of puberty. The patient is at a higher risk of osteoporosis increase if normal peak bone mass is not achieved. Therefore, individual’s future resistance to fractures can be predicted by the amount of bone mass increased throughout the pediatric years (Gordon et al., 2004). Biochemical tests performed on blood or urine samples can demonstrate the bone metabolism rate and bone metabolic processes (Calvo et al., 1996). But, there are a few studies that have examined the bone metabolism rate in CD young patients (Mora et al., 1999, Pratico et al., 1997). It was also found that the alteration rate of bone metabolism in children with untreated possibly can cause osteopathy (Barera et al., 2004).

**Gluten free diet:** The best way for management of bone disorder and calcium deficiency in CD patients is still contradictory. Nutritional status of these patients is affected by length of time that the disease has been undiagnosed, the amount of injury to the GI tract, and the grade of mal-absorption (Niewinski, 2008). A constant and strict GFD in children and adolescents with CD can help them to improve normal bone density (Mora et al., 1999, Mora et al., 1993), but there is no evidence that the highest point of bone mass level can be attained or preserved for many years, just similar to healthy population. Early diagnosis and treatment of CD children changes inflammatory process and stops bone-mass-gaining damage, therefore, the best treatment period is within childhood. In a longitudinal study (Barera et al., 2000) on children with CD, after 1 year of observing GFD, their BMD became similar to those of healthy control group. Also another study (Kavak et al., 2003) in CD children demonstrated that following a strict GFD has increased bone mineralization even after a year. It was also reported in another study (Szathmári et al., 2001) that after being on a GFD for 3 years,
children and adolescents with CD had normal or even upper radius BMD level than controls, but the bone size stayed low. In a study (Sdepanian et al., 2003) on BMD in young CD patients who followed GFD, it was demonstrated that BMD of the control children was higher than adolescents with CD but no difference was observed between that of the control group and children with CD. These findings indicated that in adolescents the time between appearance of symptoms and diagnosis was longer than the detection time of children, this made them experience more bone injury and more malnutrition. In adult CD patients bones disease treatment with GFD is a rational approach (Bonura, 2009, Hill et al., 2005). However, GFD seldom can have normal BMD in adulthoods (Bianchi and Bardella, 2002, Capriles et al., 2009). In another study (Larussa et al., 2012) it was demonstrated that after adherence to a strict GFD for a long-term, 74% of patients showed low BMD; 76% osteopenia, and 24% showed osteoporosis.

At present, the only effective treatment for CD is a strict and constant GFD, however, it is still unknown whether only GFD is sufficient to correct the bone alterations and whether these metabolic bone diseases are reversible. Searching the literature about the effects of GFD on bone modification in CD reveals conflicting consequences. In other words, some studies indicated that the risk of low BMD in CD patients on a GFD has significantly reduced (McGough and Cummings, 2005, Passananti et al., 2012). But, the results of other studies (Kaukinen et al., 2007) represented that patients with constant small-intestinal mucosal villous atrophy, even with following a strict GFD and absence of symptoms, had an elevated risk for osteoporosis. Certainly, CD patients’ bone metabolism modifications and bone mineral loss require appropriate management (Holmes et al., 1989).

Age and BMD improvement in children with CD: In a study, Zanchetta et al. reported that 93% of children who began treatment with GFD before the age of 4 years, attained normal spine BMD values. However, only 50% of patients who were older at the time of diagnosis and treatment reached normal BMD. The authors reported that children older than 4 years suffered a longer period between symptoms and diagnosis compared with younger infants (Zanchetta et al., 1995). In another study, Sdepanian et al. indicated that BMD was significantly higher in children with CD compared with the control group but BMD in adolescent with CD on GFD was significantly lower than that of the control participants; these findings demonstrated that longer time interval between signs and diagnosis in adolescents caused them suffer more from malnutrition and bone damage than children (Sdepanian et al., 2003).

Frequently, literature confirmed existence of a relationship between patients’ age at the time of intervention and the observed improvements. The results are different, some studies agree that children start GFD at a younger age (Scotta et al., 1997, Tau et al., 2006); but other studies explained that BMD also increased in older children in comparison with the control group after one year of receiving GFD (Kavak et al., 2003, Tau et al., 2006). Mora et al. (Mora et al., 1999), in a study compared children and adolescents with CD and determined that independent from GFD, starting the long-standing diet before or during puberty has caused normal BMD. Also, Scotta et al. (Scotta et al., 1997), stated that the age of diagnosis and the period of GFD extensively affect spine BMD.

The length of treatment needed to restore bone mass in CD children: Several studies evaluated bone mass in celiac children. Numerous authors reported reduced total body BMD and spine before treatment with GFD (Exner et al., 1978, Mora et al., 1999, Mora et al., 1998, Muzzo et al., 2000, Scotta et al., 1997). Szathmári et al. stated that after adherence of GFD for three or more years, adolescent and children with CD have normal or even upper radius mineral density rates than controls (Szathmári et al., 2001). In a longitudinal study bone mass of very young celiac children was assessed, it was reported that increase of BMD was two-fold greater than its increase in the area, demonstrating that GFD
therapy raises bone mineralization in addition to the increment due to bone growth (Tau et al., 2006). In the very young patients, it was 0.10g/cm² during the approximately 14 months period of observation, but in normal cases, increase of the spine BMD was respectively 0.05g/cm² and 0.02g/cm² at 2 and 10 years of age during 1 year period (Zanchetta et al., 1995). Mora et al. reported a respectively increase of 0.06 g/cm² and 0.05 g/cm², after 1.4 years on GFD in spine and whole-body BMD of children with CD. BMD was reported as normal at the end of the study (Mora et al., 1998). The duration of cure needed to repair bone mass has not been clear yet. Rea et al. reported that 1 year of GFD is enough to gain whole restoration of BMD (Rea et al., 1998). In another study (Bianchi and Bardella, 2002), it was found that some patients’ recovery of bone mass happened after only 3–7 months on GFD, while others’ recovery occurred after 1.5 years therapy. They reported that patients with a shorter symptomatic period (5.3 months between first symptoms and diagnosis) recover more completely in comparison with patients suffering longer periods of untreated CD. Possibility of full recovery of the genetically predisposed peak bone mass and minimum period of getting GFD needed for normalization of BMD is not clear. Some studies have demonstrated that 1 year is enough for the increment of the bone mass values to levels similar to those found in the normal population (Kavak et al., 2003, Mora et al., 1998), however other researchers have shown that there was a significant increase within 1 year, although the normal standards were not attained (Kalayci et al., 2001, Margoni et al., 2012).

**Conclusions**

Several studies have reported that low BMD is present in patients with untreated CD. Decreased BMD and BMC have been frequently observed in children and adolescents with untreated CD. Early beginning to cure CD children caused significantly greater bone metabolism rates. The best management of bone disorder and calcium deficiency in CD patients is controversial. Length of time through which the disease is undiagnosed, the amount of injury to the GI tract, and the grade of mal-absorption affect nutritional status of these patients. A constant and strict GFD in children and adolescents with CD can help improve normal bone density, but there is no evidence that an optimum highest point of bone mass level can be attained or that it can be preserved for many years similar to healthy population. Further, the age and duration of intervention needed to repair bone mass are still not clear.

**Acknowledgments**

This research was funded by the Isfahan University of Medical Sciences, Isfahan, Iran.

**Author contributions**

Paknahad Z contributed in the conception of the work. Mohammad Parast V searched data bases and extracted findings. Mohammad Parast V and Paknahad Z wrote the manuscript. Paknahad Z revised the manuscript. All authors approved the final version of the manuscript, and agreed for all aspects of the work.

**Conflicts of Interest**

The author declares no conflict of interest.

**References**


Celiac disease, gluten-free diet, and bone mass density.

The American journal of clinical nutrition. 72 (1): 71-75.


Celiac disease, gluten-free diet, and bone mass density.


